We narrowed to 4,405 results for: pes

#1000000105

Collection of genes and mutations for reference pathway signatures and phenotypes to compare with those derived from cancer alleles; represent over 25 cellular signaling pathways and processes

Jesse Boehm

April 24, 2017

Academic Institutions and Nonprofits only

#102263

lamB, ompC double knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102259

ompF deletion strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102265

ompC, ompF double knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102256

ompA deletion strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102258

ompC deletion strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102261

ompA, ompC double knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102262

ompA, ompF double knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102264

lamB, ompF double knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102257

lamB deletion strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102260

ompA, lamB double knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102269

lamB, ompC, ompF triple knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 14, 2017

Academic Institutions and Nonprofits only

#102268

ompA, ompC, ompF triple knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 14, 2017

Academic Institutions and Nonprofits only

#102266

ompA, lamB, ompC triple knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#102267

ompA, lamB, ompF triple knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#67755

a derivative of E. coli strain NCM3722 which has been cured of the F plasmid

Suckjoon Jun

Brown et al Genome Announc. 2015 Aug 6;3(4). pii: e0

Aug. 20, 2015

Academic Institutions and Nonprofits only

#102270

ompA, lamB, ompC, ompF quadruple knockout strain for overproduction of outer membrane proteins

Jack Leo

Meuskens et al Front Cell Infect Microbiol. 2017 Nov 7;

Nov. 10, 2017

Academic Institutions and Nonprofits only

#18916-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-rev-ChR2(H134R)-mCherry (#18916). In addition to the viral particles, you will also receive purified AAV-FLEX-rev-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, cre-dependent, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al J Neurosci. 2008 Jul 9. 28(28):7025-30.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#98747-AAV5

Ready-to-use AAV5 particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV preparations are suitable purity for injection into animals.

Nathaniel Heintz, Alexander Nectow, Eric Schmidt

Nectow et al Cell Rep. 2017 Apr 18;19(3):655-667. doi

Sept. 28, 2018

Academic Institutions and Nonprofits only

#157970-AAV.A12.T

Ready-to-use AAV44.9(E531D) in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A01.T

Ready-to-use AAV2 in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A09.T

Ready-to-use AAV6 in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A11.T

Ready-to-use AAV44.9 in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A10.T

Ready-to-use AAV6(dbY-F+T-V) in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A07.T

Ready-to-use AAV2 (trpYF) in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A06.T

Ready-to-use AAV2 (trpYF) in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A04.T

Ready-to-use AAV2 (Y444F) in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A05.T

Ready-to-use AAV2 (Y444F) in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A08.T

Ready-to-use AAV2(4pMut)dHS in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A03.T

Ready-to-use AAV2 in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A02.T

Ready-to-use AAV2 in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#98747-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Nathaniel Heintz, Alexander Nectow, Eric Schmidt

Nectow et al Cell Rep. 2017 Apr 18;19(3):655-667. doi

Sept. 27, 2023

Academic Institutions and Nonprofits only

#213917-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213943-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213947-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_GCaMP6f (#213947). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213939-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_GCaMP6f (#213939). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213859-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_GCaMP6f (#213859). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213833-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213918-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_jGCaMP8m (#213918). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_jGCaMP8m plasmid DNA. Expression of jGCaMP8m under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213941-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe3_ChR2_mCherry (#213941). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the PV+ basket cell-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213833-AAV5

Ready-to-use AAV5 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#218792-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_dTomato_nlsdTomato (#218792). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the Lamp5 interneuron-targeting enhancer. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213940-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe3_dTomato_nlsdTomato (#213940). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the PV+ basket cell-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213936-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_dTomato_nlsdTomato (#213936). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213937-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_ChR2_mCherry (#213937). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213829-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_dTomato_nlsdTomato (#213829). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213944-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_dTomato_nlsdTomato (#213944). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213814-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe10_dTomato_nlsdTomato (#213814). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E10. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213943-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213855-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_dTomato_nlsdTomato (#213855). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only